Valuation: CSL Limited

Market Cap 67.6B 60.42B 55.35B 50.43B 94.54B 6,415B 96.6B 660B 267B 3,379B 254B 248B 10,675B P/E 2027 *
23.3x
P/E 2028 * 21x
Enterprise Value 76.82B 68.66B 62.89B 57.3B 107B 7,289B 110B 750B 303B 3,840B 288B 282B 12,130B EV / Sales 2027 *
4.88x
EV / Sales 2028 * 4.69x
Free-Float
99.97%
Yield 2027 *
2.13%
Yield 2028 * 2.26%
1 day-0.61%
1 week+2.45%
Current month-0.40%
1 month+14.02%
3 months+60.84%
6 months+60.72%
Current year+15.80%
1 week 192.67
Extreme 192.67
202.85
1 month 175
Extreme 175
202.85
Current year 90
Extreme 90
202.85
1 year 90
Extreme 90
202.85
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2026
Director of Finance/CFO 52 06/10/2025
Chief Operating Officer - 30/04/2025
Director TitleAgeSince
Director/Board Member 72 16/10/2018
Director/Board Member 70 01/02/2011
Director/Board Member 71 08/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26 Free

Director

523 0.0001%
26/08/26 Free 317 0.0001% -
26/08/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.65%+2.45%+13.99%-16.03% 67.63B
-0.46%+10.80%+63.52%+154.48% 1,263B
-0.97%+2.56%+43.25%+81.96% 658B
-2.05%+1.12%+32.47%+102.74% 521B
-1.54%+1.61%+53.42%+67.10% 391B
-0.78%+2.13%+72.55%+44.25% 369B
-1.69%+2.75%+32.49%+54.35% 307B
-0.72%+8.08%+11.15%+34.09% 290B
-0.12%+5.96%+55.97%+78.44% 252B
-0.21%+9.16%+42.19%+112.41% 212B
Average -0.60%+5.51%+42.10%+71.38% 432.96B
Weighted average by Cap. -0.45%+6.53%+48.60%+95.65%

Financials

2027 *2028 *
Net sales 15.75B 14.08B 12.9B 11.75B 22.03B 1,495B 22.51B 154B 62.11B 788B 59.11B 57.86B 2,488B 16.31B 14.58B 13.35B 12.17B 22.81B 1,548B 23.31B 159B 64.31B 815B 61.19B 59.9B 2,576B
Net income 2.82B 2.52B 2.31B 2.1B 3.94B 267B 4.03B 27.52B 11.11B 141B 10.57B 10.35B 445B 3.14B 2.81B 2.57B 2.35B 4.4B 298B 4.49B 30.72B 12.4B 157B 11.8B 11.55B 497B
Net Debt 9.22B 8.24B 7.55B 6.88B 12.89B 875B 13.17B 90.03B 36.34B 461B 34.58B 33.85B 1,455B 8.82B 7.88B 7.22B 6.58B 12.34B 837B 12.6B 86.16B 34.78B 441B 33.09B 32.4B 1,393B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
02/11/26 A$199.85 -0.65% 83,712
02/11/26 A$201.16 +0.21% 719,742
30/10/26 A$200.73 +1.64% 1,374,203
29/10/26 A$197.50 +0.20% 924,119
28/10/26 A$197.10 +0.16% 1,218,969
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
141.16USD
Average target price
133.90USD
Spread / Average Target
-5.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited